Ginkgo added 13 new Cell Programs to the Foundry platform in Q1 2023
Recent acquisition of the adeno-associated virus (AAV) capsid engineering platform assets of StrideBio is advancing Ginkgo's capabilities and commercial potential in gene therapy
Read more at prnewswire.com